Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.44 |
| ▸ | CASP6 | P55212 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142699 | 0.87 | KDM4E (0.60) | HTTKDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13462246 | 0.87 | MAOA (0.49) | HTTKDM4ESMN1; SMN2RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL640343 | 0.84 | MAOA (0.47) | HTTKDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1506959 | 0.82 | HTR1A (0.53) | HTTKDM4ENPC1GAAL3MBTL1 | |
| SCHEMBL28527656 | 0.81 | PAX8 (0.55) | HTTKDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL11307415 | 0.80 | KDM4E (0.75) | HTTKDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL10692355 | 0.80 | MAOA (0.55) | HTTKDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2224753 | 0.79 | HSP90AA1 (0.62) | HTTKDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13036181 | 0.77 | KMT2A (0.50) | HTTKDM4ESMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL9886094 | 0.77 | MAOA (0.59) | HTTKDM4ESMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| EP-3424926-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINS, THEIR PRODUCTION AND UTILISATION AS MEDICINE | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-20180291025-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-10-11 | — | — | US | disclosed |
| US-10023574-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180057495-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-01 | — | — | US | disclosed |
| CN-107674077-A | 8 [base of 3 amino piperidine 1] Xanthine compounds, its preparation method and purposes as pharmaceutical preparation | 勃林格殷格翰制药两合公司 | 2018-02-09 | — | — | CN | disclosed |
| CN-105001222-B | 8 [base of 3 amino piperidine 1] Xanthine compounds, its preparation method and purposes as pharmaceutical preparation | 勃林格殷格翰制药两合公司 | 2017-11-07 | — | — | CN | disclosed |
| US-20170081329-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9556175-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-20160194327-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-07 | — | — | US | disclosed |
| EP-1532149-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-2070539-A1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2060573-A2 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-20 | — | — | EP | disclosed |
| EP-2058311-A2 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-13 | — | — | EP | disclosed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-7407955-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-08-05 | — | — | US | disclosed |
| EP-1532149-A2 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-25 | — | — | EP | disclosed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | disclosed |
| WO-2004018468-A2 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | HTT 3663/4885KDM4E 829/4885SMN1; SMN2 2325/4885 |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | HTT 3460/4885KDM4E 779/4885SMN1; SMN2 1963/4885 |
| US-20180057495-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | HTT 3663/4885KDM4E 829/4885SMN1; SMN2 2325/4885 |
| US-20180291025-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | HTT 3663/4885KDM4E 829/4885SMN1; SMN2 2325/4885 |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | HTT 3460/4885KDM4E 779/4885SMN1; SMN2 1963/4885 |
| US-20170081329-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | HTT 3663/4885KDM4E 829/4885SMN1; SMN2 2325/4885 |
| US-20160194327-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | HTT 3663/4885KDM4E 829/4885SMN1; SMN2 2325/4885 |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | HTT 4106/4885KDM4E 1974/4885SMN1; SMN2 2910/4885 |
| US-10023574-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | HTT 3663/4885KDM4E 829/4885SMN1; SMN2 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.